EAST RUTHERFORD, N.J., Oct. 25 /PRNewswire-FirstCall/ -- Cambrex Bio
Science Walkersville, Inc., a subsidiary of Cambrex Corporation (NYSE: CBM),
is pleased to announce that it has signed an exclusive license agreement with
The Johns Hopkins University, Baltimore, MD, for access to two novel,
quantitative assay technologies for the detection of contaminants such as
pathogens in drugs, beverages and food. The technologies will be used to
develop products and services for use in microbial testing of drugs, vaccines,
biopharmaceuticals, cell therapeutics, nutraceuticals, cosmetics and food.
(Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO )
"This license from Johns Hopkins extends our capabilities to identify and
quantify pathogens utilizing the recently licensed Epoch MGB Eclipse(TM)
technology and the recently acquired Genolife know-how," commented Dave
Eansor, President Cambrex Bioproducts. "We will leverage our success and
experience with endotoxin and mycoplasma detection testing to establish a
market-leading position in patient and consumer product safety testing for the
drug, food and personal care markets."
About Cambrex Bio Science Walkersville
Cambrex Bio Science Walkersville, Inc., a subsidiary of Cambrex
Corporation (NYSE: CBM), is a leading provider of normal human cells systems;
research and therapeutic media; cell therapy services; endotoxin detection
products, services and WinKQCL(R) software; electrophoresis and chromatography
products; products and services for rapid testing, including custom assay
development; regulatory services; and therapeutic commercialization solutions.
About Cambrex Corporation
Cambrex is a global, diversified life science company dedicated to
providing high quality products and services to accelerate the discovery,
development, and manufacturing processes of human therapeutics. The Company
employs approximately 1900 worldwide. For more information, please visit our
website at http://www.cambrex.com.
Forward Looking Statements
This news release contains "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995 and Rule 3B-6 under
The Securities Exchange Act of 1934, including, without limitation, statements
regarding expected performance, especially expectations with respect to sales,
research and development expenditures, earnings per share, capital
expenditures, acquisitions, divestitures, collaborations, or other expansion
opportunities. These statements may be identified by the fact that words such
as "expects," "anticipates," "intends," "estimates," "believes" or similar
expressions are used in connection with any discussion of future financial and
operating performance. The forward-looking statements contained herein are
based on current plans and expectations and involve risks and uncertainties
that could cause actual outcomes and results to differ materially from current
expectations including but not limited to, global economic trends,
pharmaceutical outsourcing trends, competitive pricing or product
developments, government legislation and/or regulations (particularly
environmental issues), tax rate, technology, manufacturing and legal issues,
unfavorable results shipments, changes in foreign exchange rates, performance
of minority investments, un-collectable receivables, loss on disposition of
assets, cancellation or delays in renewal of contracts, and lack of suitable
raw materials or packaging materials. For further details and a discussion of
these and other risks and uncertainties, investors are cautioned to review the
Cambrex Annual Report on Form 10-K, including the Forward-Looking Statement
and Risk Factors That May Impact Future Results sections therein, and other
filings with the Securities and Exchange Commission. The Company undertakes
no obligation to publicly update any forward-looking statement, whether as a
result of new information, future events or otherwise.
SOURCE Cambrex Corporation
 back to top
Related links:
http://www.cambrex.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO
Company News On-Call:
http://www.prnewswire.com/comp/134219.html
CONTACT:
Anne-Marie Hess, Director, Investor Relations
& Corporate Communications, +1-201-804-3062, or
annemarie.hess@cambrex.com, of Cambrex Corporation
|
